Sofosbuvir and vedolizumab knocked back

The Pharmaceutical Benefits Advisory Committee has rejected submissions for the PBS listing of sofosbuvir (Sovaldi) for hepatitis C and vedolizumab (Entyvio) for moderate to severe ulcerative colitis.

Latest

Trending